Allergan (NYSE:AGN) EVP William Meury sold 24,425 shares of Allergan stock in a transaction on Thursday, May 17th. The stock was sold at an average price of $154.59, for a total value of $3,775,860.75. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
NYSE AGN opened at $154.21 on Tuesday. Allergan has a 12 month low of $142.81 and a 12 month high of $256.80. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.10 and a quick ratio of 0.94. The stock has a market cap of $53.72 billion, a PE ratio of 9.43, a P/E/G ratio of 1.13 and a beta of 1.17.
Allergan (NYSE:AGN) last posted its quarterly earnings data on Monday, April 30th. The company reported $3.74 EPS for the quarter, beating the Zacks’ consensus estimate of $3.36 by $0.38. Allergan had a negative net margin of 11.94% and a positive return on equity of 8.53%. The company had revenue of $3.67 billion during the quarter, compared to the consensus estimate of $3.59 billion. During the same quarter in the prior year, the company posted $3.35 EPS. The company’s quarterly revenue was up 2.8% compared to the same quarter last year. analysts expect that Allergan will post 16.03 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 15th. Stockholders of record on Friday, May 18th will be paid a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.87%. The ex-dividend date of this dividend is Thursday, May 17th. Allergan’s dividend payout ratio is currently 17.61%.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Prosight Management LP purchased a new stake in shares of Allergan during the 4th quarter worth about $16,031,000. Tower Research Capital LLC TRC grew its holdings in shares of Allergan by 479.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,768 shares of the company’s stock worth $289,000 after purchasing an additional 1,463 shares during the period. Canyon Capital Advisors LLC grew its holdings in shares of Allergan by 248.4% during the 4th quarter. Canyon Capital Advisors LLC now owns 501,494 shares of the company’s stock worth $82,034,000 after purchasing an additional 357,559 shares during the period. Vantage Financial Partners Ltd. Inc. grew its holdings in shares of Allergan by 23.8% during the 4th quarter. Vantage Financial Partners Ltd. Inc. now owns 6,250 shares of the company’s stock worth $1,018,000 after purchasing an additional 1,200 shares during the period. Finally, Spark Investment Management LLC purchased a new stake in shares of Allergan during the 4th quarter worth about $3,157,000. 79.57% of the stock is owned by institutional investors.
Several research analysts have recently issued reports on the company. Leerink Swann lifted their price target on Allergan from $237.00 to $242.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 7th. JPMorgan Chase set a $265.00 price target on Allergan and gave the stock a “buy” rating in a research note on Thursday, March 15th. Cantor Fitzgerald set a $191.00 price target on Allergan and gave the stock a “hold” rating in a research note on Friday, April 27th. Vetr downgraded Allergan from a “strong-buy” rating to a “buy” rating and set a $183.43 price target for the company. in a research note on Thursday, March 15th. Finally, Deutsche Bank reaffirmed a “buy” rating on shares of Allergan in a research note on Thursday, April 12th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and fifteen have given a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $214.81.
Allergan Company Profile
Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.